What future CHF therapy, page-6

Fair question Antibody and would be best answered if you have a direct line to TEVA ( which unfortunately we don't). So next best case (imo) is the very old and commercially accepted principle of "put your money where your mouth is".

So if you look at TEVA and the way they are behaving ..well there actions are quite exciting am starting to think that maybe a paradigm shift in treating very ill CHF patients is on the way..
As of 4/2/2016 103 study locations ( up from 91 in early jan16 and 53 in Dec15). Of these 10 in Russia and many more in Europe. In all fairness the Prof has been saying for a while now that TEVA are leading the discussions with both Clinicians and FDA and this definitely supports his statement and the current strong relationship with TEVA.

Furthermore ( as noted in last JP Morgan presentation - page 13 ) , the next CHF update will be a joint announcement by TEVA/MSB (early April 16).. looking forward to that.

Finally I here the Fund managers are very cool...as they expect a turnaround in SP. Possibly explains why the majority have not only not sold any shares but added to there portfolio on the Nasdaq raising. Fidelity ( No 1 health fund in US)....took a swag.

Sorry Anti ..still qualify and DYOR.